While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant ...

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX ...

These dual engines of human biology and therapeutic innovation propel breakthrough progress in medicine. This article reviews the Vertex strategy to discover, develop and manufacture breakthrough ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

medicine Alyftrek, recently. Let us understand the company’s strengths and weaknesses to better analyze how to play the stock given the recent increase in price. Vertex holds a dominant position ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) treatment has been approved by the Medicines and Healthcare ...

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain medicine in the US in more than 20 years. The oral NaV1.8 inhibitor has been ...

The wholesale cost for Vertex’s twice-daily medicine is set at $15.50 per 50 milligram tablet. Vertex’s drug was approved to treat moderate-to-severe acute pain. The company has been pushing ...

Vertex Pharmaceuticals (NASDAQ:VRTX) ended a four-day winning streak on Thursday after UnitedHealth (NYSE:UNH) placed its new pain medication Journavx in a less favorable Tier 3 coverage in two ...